Humana beat Wall Street’s first-quarter earnings estimates on Wednesday, but investors weren’t impressed. The stock dropped as much as 7.4% in premarket trading after the health insurer kept its full-year profit forecast unchanged while rivals raised theirs.
Adjusted earnings came in at $10.31 per share, beating analyst estimates of around $10.19–$10.20. Revenue rose to $39.65 billion, up from $32.11 billion a year ago, and also topped expectations of $39.37 billion.
But the headline beat wasn’t enough to lift sentiment.
$HUM Q1 2026 earnings: Massive Growth Masks a Severe Earnings Reset
Humana's 23% YoY revenue surge looks impressive on the surface, driven by an accelerating influx of 1.1 million new Individual Medicare Advantage (MA) members in Q1. However, this volume is not reaching the…
— Finsee (@Finsee_main) April 29, 2026
Morningstar analyst Julie Utterback pointed out that investors may have expected Humana to raise its outlook given the strong start to the year. That didn’t happen.
The company held its full-year adjusted earnings guidance at at least $9 per share. On a reported basis, the outlook was actually cut — down to at least $8.36 a share from the previous forecast of at least $8.89.
The reduction reflects charges tied to a multiyear transformation program, including severance, asset impairments, and outside consulting costs.
A key part of the story is Humana’s lower Medicare Advantage Star Ratings for 2026. These ratings, on a scale of one to five stars, are tied directly to bonus payments from the federal government. Lower ratings mean fewer bonuses.
The company has been flagging this headwind for some time. Net income for Q1 came in at $9.83 per share, down from $10.30 a year earlier — a direct reflection of that pressure.
CEO Jim Rechtin said medical service use and costs remained in line with expectations. But he noted the gap between what the company spends on care and what the government pays has grown compared to last year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
One bright spot: Humana’s insurance segment benefit ratio — the share of premiums spent on medical costs — came in at 89.4% for Q1. That was better than the company’s own outlook of just under 90%, and better than the 89.7% Wall Street had expected.
The lower the ratio, the better for the insurer. A reading below 90% is generally seen as well-managed.
For Q2, Humana expects that ratio to rise to slightly above 91%, which signals some cost pressure ahead.
The company also noted that overall medical and pharmacy cost trends are running slightly better than expected, which Cantor analyst Sarah James described as one of the few positives in the print.
Still, James flagged concerns. “HUM has several signals that the back-half of the year could be difficult to manage,” she said, calling the premarket reaction “a warning sign.”
Humana said it will adjust benefits as needed to stay on track for stable margins. The U.S. government announced earlier this month it would raise Medicare Advantage payments by 2.48% on average in 2027.
The stock was last down around 2% in premarket trading after initially dropping 7.4%.
The post Humana (HUM) Stock Falls After Earnings Beat Fails to Lift Forecast appeared first on CoinCentral.
